3rd Annual Cardiometabolic Health Congress, Boston
The 2008 Cardiometabolic Health Congress (CMHC) will hold its third annual meeting October 15-18, 2008, at the Sheraton Boston Hotel. Over 1,000 clinicians will attend educational sessions focusing on cardiometabolic risk, including the prevention and management of diabetes, obesity, hypertension, atherosclerosis, dyslipidemia, and chronic kidney disease. The CMHC agenda, faculty, and general congress information can be found at http://www.cardiometabolichealth.org.
The congress will evaluate novel and emerging therapies that combat the epidemic of obesity, diabetes, and... cardiovascular disease. CMHC features over 50 world-renowned experts translating cutting-edge science into practical approaches to manage the problems associated with metabolic syndrome and cardiovascular risk. Physicians and allied health professionals can earn up 37.5 continuing medical education credits.
"The management of diabetes is evolving quickly, with new therapeutic agents and several landmark studies reporting this year," said John Buse, MD, PhD, CDE, chief of the Division of Endocrinology at the University of North Carolina School of Medicine at Chapel Hill. "Discussing these advances in the context of cardiovascular risk management is critical for establishing best practices in patient care."
The CMHC late-breaking clinical trials data session will provide healthcare professionals with the most recent findings from large, ongoing clinical trials and discuss how the data will impact their practice.
"Cardiometabolic (CM) risk is the new paradigm that challenges us to understand patients' risk for developing cardiovascular disease and diabetes. The 2008 CMHC is the place to hear all the latest information on CM risk," said Christopher Cannon, MD, senior investigator in the TIMI Study Group at Brigham and Women's Hospital and associate professor of medicine at Harvard Medical School.
An unprecedented group of prestigious medical organizations, including the American Diabetes Association, the American Heart Association (Councils on Clinical Cardiology; Atherosclerosis, Thrombosis, and Vascular Biology; High Blood Pressure Research; Cardiovascular Nursing; Epidemiology and Prevention; and Nutrition, Physical Activity, and Metabolism); the Endocrine Society; the American Society of Hypertension, and the National Kidney Foundation, among many others, have been supporting CMHC for the past three years.
The 2008 CMHC is co-chaired by Christie M. Ballantyne, MD; Robert H. Eckel, MD; Richard W. Nesto, MD; and Jay S. Skyler, MD.
The congress will evaluate novel and emerging therapies that combat the epidemic of obesity, diabetes, and... cardiovascular disease. CMHC features over 50 world-renowned experts translating cutting-edge science into practical approaches to manage the problems associated with metabolic syndrome and cardiovascular risk. Physicians and allied health professionals can earn up 37.5 continuing medical education credits.
"The management of diabetes is evolving quickly, with new therapeutic agents and several landmark studies reporting this year," said John Buse, MD, PhD, CDE, chief of the Division of Endocrinology at the University of North Carolina School of Medicine at Chapel Hill. "Discussing these advances in the context of cardiovascular risk management is critical for establishing best practices in patient care."
The CMHC late-breaking clinical trials data session will provide healthcare professionals with the most recent findings from large, ongoing clinical trials and discuss how the data will impact their practice.
"Cardiometabolic (CM) risk is the new paradigm that challenges us to understand patients' risk for developing cardiovascular disease and diabetes. The 2008 CMHC is the place to hear all the latest information on CM risk," said Christopher Cannon, MD, senior investigator in the TIMI Study Group at Brigham and Women's Hospital and associate professor of medicine at Harvard Medical School.
An unprecedented group of prestigious medical organizations, including the American Diabetes Association, the American Heart Association (Councils on Clinical Cardiology; Atherosclerosis, Thrombosis, and Vascular Biology; High Blood Pressure Research; Cardiovascular Nursing; Epidemiology and Prevention; and Nutrition, Physical Activity, and Metabolism); the Endocrine Society; the American Society of Hypertension, and the National Kidney Foundation, among many others, have been supporting CMHC for the past three years.
The 2008 CMHC is co-chaired by Christie M. Ballantyne, MD; Robert H. Eckel, MD; Richard W. Nesto, MD; and Jay S. Skyler, MD.